GlassScriptPhysician profile
Chitra Lal Lal
NPI 1437197175
$93,757.92
in general payments reported to CMS, 2019-2025
12 companies · $413 in 2025
The $413 reported for 2025 was less than what a typical Sleep Medicine (Internal Medicine) provider received nationally (typical 2025 total: $447).
See the full distribution for Sleep Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $5,680 · 2021: $29K · 2022: $9,725 · 2023: $16K · 2024: $4,277 · 2025: $413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Food and Beverage: $1,492 · Travel and Lodging: $1,174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,325.00 |
| Food and Beverage | $1,491.50 |
| Travel and Lodging | $1,173.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $83,255.34 | 2019-2025 | |
| Idorsia Pharmaceuticals US INC | $3,882.81 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $3,589.71 | 2023-2025 | Sunosi |
| Glaxosmithkline, LLC. | $2,000.00 | 2020 | |
| United Therapeutics Corporation | $306.09 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $200.00 | 2025 | Lumryz |
| Itamar Medical INC | $158.88 | 2024 | Watchpatone |
| Harmony Biosciences LLC | $94.99 | 2022 | |
| Mylan Specialty L.P. | $90.78 | 2019 | |
| Genentech USA, INC. | $71.83 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.68 | 2025 | |
| Insmed, INC. | $52.81 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chitra Lal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.